Tempest Therapeutics, Inc.
TPSTHealthcare|Biotechnology|US
$0.38
+0.01 (+1.44%)
Cash / Share
$0.05
Financials
Financial Snapshot
Market Cap
$7.6M
Enterprise Value
$14.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$40.5M
Cash & Investments
$779.0K
Net Cash
-$6.8M
Free Cash Flow (TTM)
-$20.7M
Operating CF (TTM)
-$20.7M
Debt/Equity
-6.94
Cash Runway & Burn Rate
Cash on Hand
$779.0K
Quarterly Burn
$5.2M
Monthly Burn
$1.7M
Est. Runway
~0.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $114.4M | $67.2M | $77.7M | $63.5M | $18.8M | $51.8M | $31.2M | $39.2M | $30.3M | $7.7M | $779.0K | |
| Operating Cash Flow | -$61.7M | -$20.3M | -$23.6M | -$41.2M | -$19.0M | -$26.0M | -$31.1M | -$27.4M | -$33.0M | -$26.8M | -$20.7M | |
| Free Cash Flow | -$64.3M | -$20.3M | -$23.7M | -$41.6M | -$19.1M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M | -$20.7M | |
| Capital Expenditure | -$2.6M | -$4.0K | -$36.0K | -$397.0K | -$50.0K | -$135.0K | -$562.0K | -$170.0K | -$435.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $54.1M | -$4.5M | $78.6M | $26.9M | $34.6M | $59.1M | $11.4M | $35.6M | $24.5M | $4.3M | $7.2M |
R&D Spending
R&D (TTM)
$3.0M
R&D Intensity
—
R&D Growth vs Prior
-75.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $653.0K | $295.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $21.6M | $14.5M | $14.4M | $27.8M | $14.4M | $17.2M | $22.5M | $17.5M | $28.5M | $12.6M | $3.0M | |
| R&D % of Revenue | 3314.1% | 4924.1% | — | — | — | — | — | — | — | — | — | |
| SG&A | $49.2M | $5.9M | $8.7M | $16.5M | $4.1M | $9.8M | $12.1M | $11.7M | $13.6M | $14.0M | $15.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $653.0K | $295.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $5.4M | $28.0K | $32.0K | $0.00 | $815.0K | $0.00 | $0.00 | $0.00 | $389.0K | $0.00 | $22.2M | |
| Gross Profit | -$4.7M | $267.0K | -$32.0K | -$1.1M | -$815.0K | $0.00 | $0.00 | $0.00 | -$389.0K | $0.00 | -$22.2M | |
| R&D | $21.6M | $14.5M | $14.4M | $27.8M | $14.4M | $17.2M | $22.5M | $17.5M | $28.5M | $12.6M | $3.0M | |
| SG&A | $49.2M | $5.9M | $8.7M | $16.5M | $4.1M | $9.8M | $12.1M | $11.7M | $13.6M | $14.0M | $15.4M | |
| Operating Income | -$81.0M | -$20.5M | -$23.1M | -$45.4M | -$19.3M | -$27.0M | -$34.6M | -$29.2M | -$42.0M | -$26.6M | -$40.6M | |
| Interest Expense | $659.0K | $0.00 | $134.0K | $0.00 | $0.00 | $1.3M | $1.6M | $1.4M | $1.3M | $207.0K | $23.0K | |
| Pretax Income | -$82.1M | -$84.6M | -$27.2M | -$44.6M | -$19.2M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M | -$40.5M | |
| Net Income | -$82.3M | -$84.6M | -$27.2M | -$44.6M | -$19.1M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M | -$40.5M | |
| EPS (Diluted) | -575.73 | -72406.33 | -263.65 | -48.77 | -612.56 | -7.80 | -3.18 | -1.91 | -1.50 | -6.33 | -4.48 | |
| EBITDA | -$79.8M | -$84.3M | -$27.0M | -$43.5M | -$18.9M | -$26.6M | -$33.5M | -$27.7M | -$40.1M | -$25.8M | -$40.2M | |
| Shares Out. (M) | 0.14 | 0.00 | 0.10 | 0.91 | 0.03 | 0.29 | 0.89 | 15.42 | 27.90 | 4.15 | 15.22 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43.9M | $15.7M | $73.3M | $63.5M | $18.8M | $51.8M | $31.2M | $39.2M | $30.3M | $7.7M | $779.0K | |
| Short-Term Investments | $70.5M | $51.5M | $4.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $116.4M | $19.7M | $83.4M | $71.1M | $19.8M | $69.0M | $33.0M | $40.4M | $31.5M | $8.3M | $1.7M | |
| Total Assets | $122.5M | $19.8M | $84.1M | $75.0M | $22.9M | $73.2M | $46.1M | $51.6M | $41.5M | $16.9M | $9.6M | |
| Total Current Liabilities | $13.2M | $4.1M | $9.8M | $12.5M | $3.2M | $20.0M | $7.3M | $9.4M | $14.2M | $3.3M | $4.5M | |
| Long-Term Debt | $0.00 | $599.0K | $383.0K | $168.0K | $0.00 | $15.1M | $10.4M | $6.3M | $0.00 | $6.9M | $0.00 | |
| Total Liabilities | $14.3M | $4.8M | $11.0M | $15.1M | $91.7M | $37.1M | $28.0M | $24.8M | $22.4M | $10.3M | $10.7M | |
| Stockholders' Equity | $108.2M | $2.2M | $71.0M | $58.5M | -$68.8M | $36.1M | $18.1M | $26.8M | $19.1M | $6.7M | -$1.1M | |
| Retained Earnings | -$250.2M | -$136.9M | -$164.1M | -$208.7M | -$71.8M | -$100.1M | -$135.8M | -$165.3M | -$207.1M | -$233.4M | -$275.3M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$61.7M | -$20.3M | -$23.6M | -$41.2M | -$19.0M | -$26.0M | -$31.1M | -$27.4M | -$33.0M | -$26.8M | -$20.7M | |
| Capital Expenditure | -$2.6M | -$4.0K | -$36.0K | -$397.0K | -$50.0K | -$135.0K | -$562.0K | -$170.0K | -$435.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$64.3M | -$20.3M | -$23.7M | -$41.6M | -$19.1M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M | -$20.7M | |
| Investing Cash Flow | $8.3M | $458.0K | $1.1M | $4.0M | -$6.0K | -$97.0K | -$562.0K | -$170.0K | -$435.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $54.1M | -$4.5M | $78.6M | $26.9M | $34.6M | $59.1M | $11.4M | $35.6M | $24.5M | $4.3M | $7.2M | |
| Issuance of Stock | $54.1M | $2.0K | $38.8M | $27.1M | $0.00 | $33.4M | $8.9M | $35.6M | $28.6M | $10.7M | $7.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$4.5M | $6.5M | -$202.0K | $0.00 | $15.0M | -$4.7M | $0.00 | -$4.4M | -$6.4M | $0.00 | |
| Stock Based Comp. | $9.2M | $6.9M | $1.4M | $0.00 | $453.0K | $1.1M | $1.6M | $2.5M | $5.3M | $3.1M | $746.0K | |
| Net Change in Cash | $706.0K | -$26.3M | $55.7M | -$9.8M | $15.6M | $33.0M | -$20.2M | $8.1M | -$9.0M | -$22.6M | -$13.5M |
Dilution Tracker
Shares outstanding grew 13196.2% over 5 years — significant dilution
Shares Outstanding
20M
5-Year Share Growth
+13196.2%
Stock Issuance (TTM)
$7.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.14 | 0.00 | 0.10 | 0.91 | 0.03 | 0.29 | 0.89 | 15.42 | 27.90 | 4.15 | 15.22 | |
| Change vs Prior % | — | -99.2% | 8730.1% | 786.0% | -96.6% | 834.2% | 204.7% | 1635.3% | 81.0% | -85.1% | 266.9% | |
| Stock Issuance | $54.1M | $2.0K | $38.8M | $27.1M | $0.00 | $33.4M | $8.9M | $35.6M | $28.6M | $10.7M | $7.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $9.2M | $6.9M | $1.4M | $0.00 | $453.0K | $1.1M | $1.6M | $2.5M | $5.3M | $3.1M | $746.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -727.1% | 90.5% | — | — | — | — | — | — | — | — | — | |
| Operating Margin % | -12406.1% | -6943.1% | — | — | — | — | — | — | — | — | — | |
| Net Margin % | -12597.2% | -28670.5% | — | — | — | — | — | — | — | — | — | |
| EBITDA Margin % | -12223.7% | -28566.1% | — | — | — | — | — | — | — | — | — | |
| FCF Margin % | -9849.9% | -6896.3% | — | — | — | — | — | — | — | — | — | |
| ROE % | -76.0% | -3796.1% | -38.3% | -76.1% | 27.8% | -78.4% | -197.2% | -110.2% | -218.8% | -393.9% | -1270.1% | |
| ROA % | -67.1% | -426.9% | -32.3% | -59.4% | -83.6% | -38.6% | -77.5% | -57.1% | -100.9% | -155.1% | -420.1% | |
| ROIC % | -74.1% | -128.9% | -30.9% | -70.5% | -94.8% | -49.4% | -86.1% | -61.5% | -121.8% | -179.5% | -628.2% | |
| R&D / Revenue % | 3314.1% | 4924.1% | — | — | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 135.7% | -54.8% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -140.8% | 105.6% | -112.0% | -3187.5% | 22.5% | 100.0% | 0.0% | 0.0% | 0.0% | 100.0% | |
| Operating Income | -12.5% | 74.7% | -12.9% | -96.4% | 57.5% | -39.8% | -28.4% | 15.8% | -44.1% | 36.8% | |
| Net Income | -12.3% | -2.8% | 67.8% | -63.9% | 57.1% | -48.0% | -26.2% | 17.4% | -41.9% | 37.2% | |
| EPS (Diluted) | 5.3% | -12476.4% | 99.6% | 81.5% | -1156.0% | 98.7% | 59.2% | 39.9% | 21.5% | -322.0% | |
| Operating Cash Flow | -22.8% | 67.1% | -16.3% | -74.3% | 53.9% | -36.5% | -19.7% | 12.0% | -20.7% | 18.8% | |
| Free Cash Flow | -15.9% | 68.4% | -16.4% | -75.7% | 54.2% | -36.8% | -21.2% | 13.0% | -21.6% | 19.8% | |
| R&D Expense | 17.4% | -32.9% | -0.7% | 93.0% | -48.3% | 19.3% | 31.2% | -22.3% | 62.7% | -55.7% | |
| SG&A Expense | -4.6% | -88.0% | 46.1% | 90.6% | -75.2% | 139.9% | 23.4% | -3.7% | 16.2% | 3.1% | |
| Total Assets | -11.6% | -83.8% | 324.4% | -10.8% | -69.5% | 220.3% | -37.1% | 12.0% | -19.6% | -59.2% | |
| Book Value / Share | -28.1% | 1593.7% | -94.5% | -90.8% | -3464.2% | 105.6% | -83.6% | -91.5% | -60.5% | 134.4% | |
| Debt | 0.0% | 0.0% | -26.0% | 690.6% | -46.1% | 660.0% | 19.3% | -6.6% | -25.6% | -47.0% | |
| Diluted Shares | 18.7% | -99.2% | 8730.1% | 786.0% | -96.6% | 834.2% | 204.7% | 1635.3% | 81.0% | -85.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-5.32
10Y Low / Med / High0.55 / 2.25 / 32.94
EV/EBITDAAt Loss
10Y Low / Med / High0.12 / 0.18 / 0.50
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.05
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -7.77 | -0.06 | -5.88 | -26.95 | -0.68 | -8.80 | -4.70 | -29.95 | -7.23 | -0.45 | -0.08 | |
| P/S Ratio | 978.71 | 16.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 5.91 | 2.15 | 2.25 | 20.51 | -0.19 | 0.55 | 0.73 | 32.94 | 15.83 | 1.79 | -5.32 | |
| EV/EBITDA | -7.46 | 0.12 | -3.23 | -26.24 | 0.18 | 0.50 | -0.12 | -31.21 | -7.17 | -0.48 | -0.36 | |
| EV/Revenue | 911.44 | -34.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-53.80
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $17.9M | $57.8M | $4.3M |
| Net Income | -$11.8M | -$3.7M | -$3.7M |
| EPS | $-2.85 | $-0.90 | $-0.89 |
| # Analysts (EPS) | 1 | 1 | 1 |